Darmiyan Executives Call FDA's Accelerated Approval of Aducanumab A Big Step in the Right Direction

San Francisco, California--(Newsfile Corp. - June 7, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/86775_figure1_550.jpg

Click image above to view full announcement.

Based in San Francisco, California, Darmiyan was incorporated in September 2016 and backed by Y-Combinator (YC) in Summer 2017. The Company has won numerous awards and recognitions including the TEDMED Hive Innovator in 2018, CABHI Innovation Award in 2019 and Fortune 40 Under 40 for healthcare in 2020 and in May 2021 an FDA Breakthrough designation for BrainSee. Darmiyan's most recent funding in 2020 was led by the global pharma giant Eisai with participation of YC and IT-Farm. Darmiyan's proprietary technology using brain MRI is patented in the US; patents are pending in Europe, Japan and China.

Ilyse Veron

Source: Darmiyan

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86775